SK Bioscience wins W300b policy funding for pneumococcal vaccine

SK Bioscience plans to expedite the late-stage clinical trial of its pneumococcus vaccine by leveraging a 300 billion won ($200 million) government fund.

The vaccine arm of SK Group said Friday that its board of directors approved an ultra-low interest loan from the Korean government-backed National Growth Fund.

The decision comes after the Fund Operations Committee nominated SK Bioscience as a recipient of the fund on Thursday.

The National Growth Fund refers to a public-private combined financ ...